DNA immunotherapy for recurrent respiratory papillomatosis (RRP): phase 1/2 study assessing efficacy, safety, and immunogenicity of INO-3107.

Morrow MP, Gillespie E, Sylvester A, Amin MR, Belafsky PC, Best SR, Friedman AD, Klein AM, Lott DG, Mau T, Paniello RC, Pransky SM, Saba NF, Tan GS, Wisotsky S, Marcus SA, Reuschel EL, Reed KS, Weiner DB, Dallas M, Skolnik JM. Nat Commun. 2025 Feb 12;16(1):1518. doi: 10.1038/s41467-025-56729-6. PMID: 39939590